Kudos to the #NCI #ComboMATCH team, including Dr. James Ford for their ongoing innovative approach to precision oncology basket trials. New concepts are still welcomed! Fantastic talk by Dr. Ford at the our ERTC Committee @SWOG @SupportingSWOG @eaonc @theNCI @Dr_R_Kurzrock

Our October Newsletter edition is available! Read about our #BreastCancer Awareness Features, a special study highlight for ComboMATCH N5, current trials on deck, and more! Check it out: https://t.co/fyrNUo97Ms

ComboMATCH/EAY191-E5 tests how well #sotorasib with or without #panitumumab can treat patients with advanced #SolidTumors. For more information: https://t.co/sGcKIHVVD9 cc: @kspencer725, @DocDustyD #PrecisionMedicine

Fascinating look at how Dr. Chris Karlovich from @theNCI is leading deep molecular analysis to power next-gen clinical trials. Platforms like iMATCH and ComboMATCH are leveraging technologies like WES, RNA-seq, and ctDNA to bring precision combination therapies.@Phase1_NCCH

Do you have advanced #cancer has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: https://t.co/00rdMtEMUk

Sentara's Molecular Diagnostics Laboratory has been chosen by the National Cancer Institute (NCI) to participate in the ComboMATCH clinical trial, a nationwide precision medicine initiative that tests multi-drug combinations for treating solid tumors.

BostonGene's #ngs assays will identify patient candidates for the biomarker-driven ComboMATCH Trial. Assignment to a treatment trial is based on actionable genetic alterations and clinical factors, with the goal of determining the effectiveness of treating cancer using a

Do you have advanced #cancer has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: https://t.co/00rdMtEMUk

The #ComboMATCH Study, led by researchers from @StanfordCancer, @MDAndersonNews, @PennCancer, & @theNCI, is testing new combinations of anti-#cancer drugs, based on the characteristics of patients’ tumors. Learn more: https://t.co/00rdMtEMUk #PrecisionMedicine

In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: https://t.co/00rdMtEMUk #PrecisionMedicine #ClinicalTrial

New 6/1/23 article in “Science” announces new National Cancer Institute (NCI) #ComboMATCH initiative. ...If not already being considered, IMHO @CassavaSciences’ #simufilam (coupled w/add’l misfolded FLNA findings) would be perfect candidate for this new study. $SAVA for #Cancers?

WATCH: Learn about ComboMATCH, a new NCI initiative that will test combinations of drugs that target specific cancer mutations. https://t.co/0Nh0L3Yanf

Protocol Activation: EAY191-N5! A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial.

NCI's ComboMATCH gears up for #PrecisionOncology trials ❌ Targeting multiple variants and #drugresistance 🔎 Drug combinations based on #tumorbiology #targetedtherapy #oncology #clinicaltrial #CancerAwareness #CancerResearch

Led by @GShapiroMDPhD at @DanaFarber, joint Alliance @eaonc @nrgorg @swog ComboMATCH trial EAY191-A3 is enrolling patients with RAS-mutated cancers to test effectiveness of enzyme blockers called kinase inhibitors. Learn more: https://t.co/3sfaeiTVKq @thenci

Intermountain Health and #MyriadGenetics Participate in #ComboMATCH https://t.co/oVEOgJGp65 @Intermountain

Proud to participate in the @theNCI’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with #cancer. Read more: https://t.co/GdgaewKSvh

NIH’s ComboMATCH initiative will test new drug combinations guided by tumor biology https://t.co/WYX7WlJY2r

#ComboMATCH Treatment Trial E5, led by @kspencer725 of @Perlmutter_CC and @DocDustyD of @UWCarbone, is a randomized phase 2 study of #sotorasib with or without #panitumumab in advanced #SolidTumors. Learn more here: https://t.co/sGcKIHVVD9 #PrecisionMedicine